ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 558

Rapid Improvements in Patient Reported Outcomes with Certolizumab Pegol in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 24 Week Results of a Phase 3 Double Blind Randomized Placebo-Controlled Study

Joachim Sieper1, Alan J. Kivitz2, A.M. Van Tubergen3, Atul A. Deodhar4, Geoffroy Coteur5, Franz Woltering6 and Robert B. M. Landewé7, 1Medical Department I, Rheumatology, Charité University Medicine, Berlin, Germany, 2Altoona Center for Clinical Research, Duncansville, PA, 3Department of Medicine, Maastricht University Medical Center, Maastricht, Netherlands, 4Oregon Health & Science University, Portland, OR, 5UCB Pharma, Brussels, Belgium, 6UCB Pharma, Monheim, Germany, 7Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: anti-TNF therapy, certolizumab pegol, pain, quality of life and spondylarthropathy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Axial spondyloarthritis (axSpA) is a form of spondyloarthritis (SpA) that includes both ankylosing spondylitis (AS) and non-radiographic axial SpA (nr-axSpA), as defined by the ASAS criteria. Both subgroups of patients (pts) have been shown to have a similar burden on Quality of Life (QoL).1 A recent survey estimated that SpA may affect up to 1.4% of the US population.2 Certolizumab pegol (CZP) is a PEGylated Fc-free anti-TNF that improved patients reported outcomes (PRO) in rheumatoid arthritis (RA).3 RAPID-axSpA (NCT01087762) is the first report of the effect of CZP on PRO in axSpA.

Methods:

The ongoing 158-Wk RAPID-axSpA trial is double-blind and placebo controlled to Wk24, dose-blind to Wk48 and then open label to Wk158. Recruited pts had adult-onset active axSpA as defined by the ASAS criteria,1 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥4, spinal pain ≥4 on a 10 point NRS, and CRP > upper limit of normal or sacroiilitis on MRI. Pts must have failed ≥1 NSAID. Pts could have been secondary failures to 1 previous TNF inhibitor. The pt population reflected the broad axSpA population, including AS pts also meeting the modified New York criteria and nr-axSpA pts who met the ASAS MRI or clinical criteria. Pts were randomized 1:1:1 to placebo (PBO), or 400mg CZP at week (Wk) 0, 2 and 4 (loading dose, LD) followed by either 200mg CZP every 2 weeks (Q2W) or 400mg CZP every 4 weeks (Q4W). Pts receiving PBO who failed to achieve an ASAS20 response at both Wks14 and 16 were rescued and randomized at Wk16 to receive CZP 200mg Q2W or CZP 400mg Q4W following LD. The primary endpoint was ASAS20 response at Wk12. PRO endpoints included SF-36 physical component summary (PCS), physical function (BASFI), total spinal pain (NRS), fatigue (NRS from BASDAI), Ankylosing Spondylitis Quality of Life (AsQoL), Sleep Problems Index II domains of the MOS Sleep scale (MOS-SPI), and SF-36 mental component summary (MCS) and domains. All PRO were analyzed on the full analysis set using analysis of covariance on change from baseline (CFB) with last observation carried forward imputation.

Results:

325 pts were randomized. Baseline characteristics were similar between groups. Improvements in the CZP-treated groups were observed in pain NRS, fatigue NRS, BASFI and AsQoL from the first measurement at Wk1 through to Wk24 compared to PBO. Pts in both CZP-treated dosage arms had greater improvements in SF-36 PCS. compared to PBO (Table). Improvements were also seen in MOS-SPI, SF-36 MCS and domains.

Conclusion:  

Both dosing regimens of CZP rapidly improved all PRO including pain, fatigue, physical function and QoL of axSpA pts. CZP effectively improved patient-relevant outcomes in the broad population of axSpA pts classified using the ASAS criteria.

References:

1. Rudwaleit M. Arthritis Rheum 2009; 60(3):717-727

2. Reveille JD. Arthritis Care Res 2012; 64(6):905-910

3. Strand VS. Ann Rheum Dis 2011; 70(6):996-1002

 


Disclosure:

J. Sieper,

UCB Pharma,

5,

UCB Pharma,

8;

A. J. Kivitz,

UCB Pharma,

5;

A. M. Van Tubergen,

UCB Pharma,

5;

A. A. Deodhar,

UCB Pharma,

2,

UCB Pharma,

5;

G. Coteur,

UCB,

1,

UCB,

3;

F. Woltering,

UCB,

1,

UCB,

3;

R. B. M. Landewé,

UCB,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rapid-improvements-in-patient-reported-outcomes-with-certolizumab-pegol-in-patients-with-axial-spondyloarthritis-including-ankylosing-spondylitis-and-non-radiographic-axial-spondyloarthritis-24-week/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology